Heal House Vitiligo Research 55 · Review
Are vitiligo treatment studies measuring outcomes with the same standards so they can be compared?
Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials
In short
Vitiligo clinical trials still measure effectiveness with different yardsticks. This makes it difficult to compare them. We reviewed 174 trials to confirm this situation.
It may not be obvious to patients, but researchers have long faced a challenge: the standards used to measure vitiligo treatment effects vary from study to study. This makes it difficult to compare which treatment is better. So in 2015, experts worldwide made a commitment: "At a minimum, these three aspects—how much color has returned, whether there were side effects, and whether the improvement is maintained—should always be measured together." This study, in which I participated as a co-investigator, examined how well that commitment has actually been kept.
Q1 How Was Compliance Checked, and Was It Being Followed?
Unfortunately, trials that followed all three aspects were still rare. We collected all 174 randomized clinical trials on vitiligo published between 2009 and 2021 and examined which standards were used. Most (about 89%) measured the degree of color return. Side effects were measured in 78%. However, only 11% of trials assessed whether the improvement was maintained. In particular, among trials conducted after 2016, only 10% (11 out of 112) reported all three aspects.
Reporting of outcome measures in vitiligo clinical trials (174 trials)
| Outcome measure | Proportion of trials reporting | In simple terms |
|---|---|---|
| Repigmentation (color return) | About 89% | Most measured |
| Side effects / adverse reactions | About 78% | Fairly measured |
| Quality of life | About 13% | Rarely measured |
| Maintenance of improvement | About 11% | Rarely assessed |
| Cosmetic satisfaction | About 2% | Rarely assessed |
Q2 Why Does This Matter to Patients?
Because if the standards vary, it is difficult to determine which treatment is truly better. One study may only look at "how much color returned." Another may not assess "how long the improvement lasts." Then the two treatments cannot be compared side by side. In particular, how long the regained color is maintained is very important to patients. Yet only about one in ten trials checked this to the end. When studies measure outcomes using the same standards, the results can be combined to form more reliable treatment guidelines. Ultimately, standardizing these measures leads to better treatments for patients.
Closing remarks
This may sound like a dry topic, but such "research quality management" ultimately determines the quality of treatments that reach patients. By confirming with numbers that the commitment has not yet been well kept, the direction for future research has become clearer. As a co-investigator, I contributed to strengthening vitiligo research.
